HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 09, September 2019 – Healthy Ageing — How Science is chipping in       » Officials in China make progress in development of new drugs       » The Science of Healthy Ageing       » Thailand Medtech landscape - Customer to Innovator       » China-Thailand Joint Research Institute on Medicine Launched in Bangkok      
INSIDE INDUSTRY
Singapore HSA approves HIV-1 infection treatment for adults
In clinical trials, biktarvy demonstrated high efficacy and zero resistance through 48 weeks

The Singapore Health Sciences Authority has approved Gilead Sciences’ Biktarvy, a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection in adults.

It is a triple combination regimen, combining bictegravir 50mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg; BIC/FTC/TAF. It is indicated for the treatment of HIV-1 infection in adults without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.

The approval was based on data from four studies: Studies 1489 and 1490 in HIV-1 infected adults with no antiretroviral treatment history, and Studies 1844 and 1878 in HIV-1 virologically-suppressed adults who switched to Biktarvy. The trials are comprised of a population of 2,414 participants, and BIC/FTC/TAF met its primary efficacy objective at 48 weeks in all four studies.

No participants in the four BIC/FTC/TAF studies developed treatment-emergent virologic resistance. No patients discontinued due to creatinine increases, proximal renal tubulopathy or Fanconi syndrome in the BIC/FTC/TAF arms at 48 weeks.

The most common adverse reactions in patients taking BIC/FTC/TAF were diarrhoea, nausea and headache.

According to data released by the Ministry of Health, there were 434 new cases of HIV reported among Singaporean residents in 2017. Of these, 71 percent were between the ages of 20 to 49.

BIC/FTC/TAF was approved by the U.S. Food and Drug Administration (FDA) on 7 February 2018, the European Commission on 21 June 2018 and the Hong Kong Department of Health on 6 September 2018.

Click here for the complete issue.

NEWS CRUNCH  
news Philip Morris International opens artificial intelligence competition to develop improved strategies for medical diagnosis
news Kaspersky partners with Temasek Polytechnic to offer technical cybersecurity courses to more Singaporeans
news Discover the Asian nutraceuticals market at Vitafoods Asia 2019
news Singapore FinTech Festival and SWITCH come together - to bring the global innovation community to Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy